State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing

Rhea-AI Filing Summary

State Street Corporation reports beneficial ownership of common stock of BioCryst Pharmaceuticals, Inc. as an institutional holder. State Street reports beneficial ownership of 15,191,098 shares of BioCryst common stock, representing 6% of the class.

State Street has no sole voting or dispositive power over these shares. It reports shared voting power over 14,586,276 shares and shared dispositive power over 15,191,098 shares, primarily through its investment management subsidiaries such as SSGA Funds Management, Inc. and various State Street Global Advisors entities.

Key Figures

Shares Beneficially Owned: 15,191,098 shares Percent of Class: 6 % Shared Voting Power: 14,586,276 shares +1 more

4 metrics

Shares Beneficially Owned 15,191,098 shares Common stock of BioCryst Pharmaceuticals reported by State Street Corporation

Percent of Class 6 % Portion of BioCryst Pharmaceuticals common stock class held beneficially

Shared Voting Power 14,586,276 shares Shares over which State Street reports shared power to vote

Shared Dispositive Power 15,191,098 shares Shares over which State Street reports shared power to dispose

Key Terms

Schedule 13G, beneficially owned, shared voting power, shared dispositive power, +1 more

5 terms

Schedule 13G regulatory

"A group has filed this schedule pursuant to 1(b)(1)(ii)(K)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: 15191098.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared power to vote or to direct the vote: 14,586,276"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared power to dispose or to direct the disposition of: 15,191,098"

investment company regulatory

"shareholders of an investment company registered under the Investment Company Act of 1940"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 08:48 AM Accepted by SEC EDGAR 08/07/2026 - 08:48 AM Learn about SEC filing dates

FAQ

What stake does State Street Corporation report in BioCryst Pharmaceuticals (BCRX)?

State Street Corporation reports beneficial ownership of 15,191,098 shares of BioCryst Pharmaceuticals common stock, representing 6% of the outstanding class, according to the Schedule 13G filed for the issuer’s common stock.

How much voting power does State Street have over BCRX shares?

State Street reports 0 shares with sole voting power and 14,586,276 shares with shared voting power. All 15,191,098 shares beneficially owned are held with shared dispositive power, not sole control.

Does State Street hold BioCryst (BCRX) shares directly or through subsidiaries?

The position is held through investment management subsidiaries, including SSGA Funds Management, Inc. and several State Street Global Advisors entities, which are identified as the relevant subsidiaries on whose behalf the securities are reported.

What percentage of BioCryst Pharmaceuticals (BCRX) does 15,191,098 shares represent?

The filing states that 15,191,098 shares of BioCryst Pharmaceuticals common stock represent 6% of the outstanding class of that security, making State Street a holder of more than five percent.

Does any other person have rights to dividends or sale proceeds of State Street’s BCRX holdings?

The Schedule 13G indicates Item 6 is “NOT APPLICABLE”, meaning no specific other person is identified as having the right to receive dividends or sale proceeds relating to more than five percent of the class.

Is this BioCryst (BCRX) Schedule 13G filing part of a group arrangement?

The filing states under Item 8 that group identification is “NOT APPLICABLE”, indicating no disclosed filing group arrangement for these BioCryst common stock holdings reported by State Street.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BIOCRYST PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09058V103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 09058V103

1

Names of Reporting Persons

STATE STREET CORPORATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14,586,276.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,191,098.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,191,098.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BIOCRYST PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 4505 EMPEROR BLVD SUITE 200, DURHAM, NORTH CAROLINA, 27703
Item 2.
(a)	Name of person filing: STATE STREET CORPORATION;
(b)	Address or principal business office or, if none, residence: ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)	Citizenship: MA
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 09058V103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15191098.00
(b)	Percent of class: 6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 14,586,276
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 15,191,098
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. NOT APPLICABLE
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. NOT APPLICABLE

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STATE STREET CORPORATION

Signature:	ELIZABETH SCHAEFER
Name/Title:	SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:	08/07/2026